Abstract Background The management of unresectable or metastatic gastrointestinal stromal tumors (GISTs) has previously been difficult as they are resistant to conventional chemotherapy and radiation. The development of imatinib mesylate has made a major impact on the management of advanced GISTs. It is apparent that there are sanctuary sites such as the central nervous system where i... https://www.markbroyard.com/deal-time-caruso-s-rhodiola-tabs-50-discount-super-buy/